IFLI - Institute for Follicular Lymphoma Innovation

Join IFLI at the American Society of Hematology (ASH) Annual Meeting. We’re thrilled to be attending ASH2024! We look forward to collaborating with the leading minds in #hematology to support the latest in innovations and breakthroughs in the industry. The IFLI - Institute for Follicular Lymphoma Innovation team will be hosting a luncheon on Saturday, December 7, from 11:00 AM to 12:30 PM. ?? ?? ?? ?? ?? Please feel free to reach out if you would like an invitation to our reception. We look forward to connecting with you soon. Stay tuned for further updates during the conference.

Please check our last report in Science Immunology on IL-2v-armed tetraspecific NK cell engagers against B Cell lymphomas.

IFLI - Institute for Follicular Lymphoma Innovation is proud to announce a $2.1 million investment in a groundbreaking four-year research collaboration with Drs. Todd Fehniger and David Russler-Germain at Washington University in St. Louis. This funding supports the study titled “Using Circulating Tumor DNA #Sequencing to Advance Frontline Treatment of #Follicular #Lymphoma." Initially, IFLI provided a $1.3 million grant in 2022 to kickstart this important research. Now, with an additional $800,000, the study will expand to include 180 patients. These patients will undergo #PhasED-Seq #ctDNA-based measurable residual disease (#MRD) testing at pre-treatment, mid-treatment, and end-of-treatment stages. This approach aims to identify pre-treatment prognostic factors and assess the depth of response to therapy more accurately than traditional imaging methods. For more details on the Washington University study or IFLI, please visit IFLI’s website at https://www.i-fli.org/

Advancing Lymphoma Research.

IFLI - Institute for Follicular Lymphoma Innovation is proud to announce a $2.1 million investment in a groundbreaking four-year research collaboration with Drs. Todd Fehniger and David Russler-Germain at Washington University in St. Louis. This funding supports the study titled “Using Circulating Tumor DNA #Sequencing to Advance Frontline Treatment of #Follicular #Lymphoma." Initially, IFLI provided a $1.3 million grant in 2022 to kickstart this important research. Now, with an additional $800,000, the study will expand to include 180 patients. These patients will undergo #PhasED-Seq #ctDNA-based measurable residual disease (#MRD) testing at pre-treatment, mid-treatment, and end-of-treatment stages. This approach aims to identify pre-treatment prognostic factors and assess the depth of response to therapy more accurately than traditional imaging methods. For more details on the Washington University study or IFLI, please visit IFLI’s website at https://www.i-fli.org/

Why is #Follicular #Lymphoma so effective at escaping current therapies? The process involves four key steps setting the stage for malignant transformation and recurrent relapses: early BCL2 activation, dysregulation of B cell dynamics, co-evolution of propitious TME/tumour ecosystems and genomic instability leading to epigenetic dysfunction. This indolent, Darwinian-like evolution of FL generates both the peculiar complexity and heterogeneity of this disease. Inspiring! https://lnkd.in/eCmNJim7 Kudos to Mélanie Collin, Guillemette Gagey, Vignesh Shanmugam, Abner Jr., Jessica Okosun, Clémentine Sarkozy, Bertrand Nadel.

Please join WiLing Wednesdays free educational webinars Series 13 - IndolentLymphoma - Session 1 Wed October 23 - details below Registration https://lnkd.in/gBN55Bm6 Sandrine Roulland Karin TARTE Clémentine Sarkozy Kim Linton With thanks to Gilead Sciences IFLI - Institute for Follicular Lymphoma Innovation Eli Lilly and Company & Lymphoma Australia

?? Dr. Sandrine Roulland, lauréate du prix Idea de l'IFLI pour la recherche sur le lymphome folliculaire !!! Le CIML (INSERM/CNRS/Aix-Marseille University) est fier d'annoncer que le Dr. Sandrine Roulland, directrice de recherche à l'INSERM et chef d'équipe au CIML, a été désignée lauréate du prestigieux prix Idea, décerné par l'IFLI - Institute for Follicular Lymphoma Innovation (IFLI). Cette distinction, qui s'inscrit dans le cadre du programme Moonshot lancé en juin 2023, récompense l'excellence scientifique et l'innovation dans la recherche sur le lymphome folliculaire. Le Dr. Sandrine Roulland, en collaboration avec le Pr. Karin TARTE de l'Université de Rennes I, a été sélectionnée pour son projet novateur intitulé "à la recherche des cellules précurseurs cancéreuses (CPC) à l'origine de la rechute du lymphome folliculaire". Le CIML se réjouit particulièrement de cette reconnaissance qui souligne l'excellence de la recherche menée au sein de notre institut. Le projet du Dr. Sandrine Roulland, qui bénéficiera d'un financement initial de deux ans avec possibilité d'extension, contribuera de manière significative à notre compréhension des mécanismes de développement et de progression du lymphome folliculaire. Le prix Idea de l'IFLI vise à approfondir notre compréhension du lymphome folliculaire en se concentrant sur le r?le des cellules précurseurs. Utilisant des technologies de pointe, cette recherche explorera les mécanismes moléculaires et les voies qui conduisent au développement de la maladie, ouvrant ainsi la voie à des traitements innovants. https://lnkd.in/dgBssXSu

IFLI - Institute for Follicular Lymphoma Innovation is thrilled to announce additional recipients of IFLI's prestigious Moonshot IDEA Award. Co-investigators Dr. Sandrine Roulland, CIML (Centre d’Immunologie de Marseille-Luminy)?and Professor Karin TARTE, Université de Rennes I (U1236 MOBIDIC research unit), both of INSERM Institut national de la santé et de la recherche médicale, were selected for their project "“Hunting Cancer Precursor Cells (CPCs) at the Origin of Follicular Lymphoma Relapse.”?Dr. Roulland and Prof. Tarte join Dr. Dinis Calado, The Francis Crick Institute, as Moonshot IDEA Award recipients. Dr. Calado's IDEA Award was previously announced for his project "“Revolutionizing Follicular Lymphoma Treatment: Targeting CPCs for a Cure.” IFLI continues to advance its mission to revolutionize the treatment of follicular lymphoma (FL) by supporting and collaborating with these world-class FL researchers and institutions. To see the joint IFLI+Inserm Roulland+Tarte Idea Award, and to learn more about IFLI's initiatives to support and catalyze FL research and development , please visit https://www.i-fli.org/ #follicularlymphoma #fl #bloodcancerresearch #cancerresearch #CPCs #commonprecursorcells

IFLI - Institute for Follicular Lymphoma Innovation is proud to announce its sponsorship of @Women in Lymphoma’s (WiL) upcoming WiLing Wednesdays webinar series. This sponsorship aligns with IFLI’s mission to support organizations, researchers and initiatives that further the understanding and treatment of lymphoma. Casulo Carla Florence Broussais-Guillaumot Ann LaCasce Clémentine Sarkozy Laurie Sehn Anna Sureda Balari Judith Trotman Paola Ghione maia ananiashvili Adalgisa Condoluci Jennifer Crombie Kate Cwynarski @Natalie Grover Eliza Hawkes @Laura Hilton LAURA KORIN @Katharine Lewis Kim Linton @Carolina Mahaud @Wendy Osborne Astrid Pavlovsky MICHELLE POON Sabrina Ranero Ferrari News (i-fli.org)